

Contains Nonbinding Recommendations

Draft Guidance on Etodolac

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Etodolac

Form/Route: Extended-Release Tablets/Oral

Recommended study: 2 studies

1. Type of study: Fasting
Design: Single-dose, two way crossover in-vivo
Strength: 600 mg
Subjects: Healthy males and nonpregnant females, general population
Additional comments:

2. Type of study: Fed
Design: Single-dose, two way crossover in-vivo
Strength: 600 mg
Subjects: Healthy males and nonpregnant females, general population

Analytes to measure (in appropriate biological fluid): Etodolac in plasma.

Bioequivalence based on (90% CI): Etodolac

Waiver request of in-vivo testing: 400 mg and 500 mg based on (i) acceptable bioequivalence studies on the 600 mg strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products.

In addition to the method above, for modified release products, dissolution profiles on 12 dosage units each of test and reference products generated using USP Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in at least three dissolution media (pH 1.2, 4.5 and 6.8 buffer) should be submitted in the application. Agitation speeds may have to be increased if appropriate. It is acceptable to add a small amount of surfactant, if necessary. Please include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation. Specifications will be determined upon review of the data submitted in the application.